Elaphron Completes FDA INTERACT Meeting, Supporting a Streamlined Development Path for EL-924
Elaphron has completed an INTERACT meeting with the U.S. Food and Drug Administration (FDA) regarding EL-924, its lead gut-localized therapeutic candidate for obesity and metabolic dysfunction. The interaction provided important regulatory alignment on a potentially streamlined development strategy for EL-924. FDA indicated that it was open to allowing reliance on the 505(b)(2) pathway for substantial portions […]